Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
PMV hopes for rezatapopt redemption
The disappointing Pynnacle trial is set to yield registrational data.
Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
How MiNK stole the NK T show
A single but durable stable disease sends the microcap's stock up 730%.
